Enanta Pharmaceuticals, Inc. Share Price
NASDAQ: ENTA | Micro CapEnanta Pharmaceuticals, Inc. Stock Performance
Open $13.77 | Prev. Close $13.79 | Circuit Range N/A |
Day Range $13.48 - $13.87 | Year Range $7.11 - $17.11 | Volume 12,959 |
Average Traded $13.59 |
Enanta Pharmaceuticals, Inc. Share Price Today
As of 31 August 2026, Enanta Pharmaceuticals, Inc.'s share price is $13.60. The stock opened at $13.77, compared to its previous close of $13.79. During today's trading session, Enanta Pharmaceuticals, Inc.'s share price traded between $13.48 and $13.87, with an average price of $13.67. Over the past 52 weeks, the stock has recorded a high of $17.11 and a low of $7.11. In terms of performance, Enanta Pharmaceuticals, Inc.'s share price has declined by 4.16% over the last six months and is up 62.10% on a year-on-year basis.
Enanta Pharmaceuticals, Inc. Share Price Chart
Enanta Pharmaceuticals, Inc. Stock Fundamentals & Key Indicators
Market Cap $290169.60 | PE Ratio (TTM) -3.54 | Dividend Yield N/A |
EPS (TTM) $-3.84 | Revenue (TTM) $65.32M | Return On Equity (TTM) -126.53% |
Profit Margin -125.36% | Debt to Equity 0.75 | Quarterly Earnings Growth YoY 46.44% |
Enanta Pharmaceuticals, Inc. Quarterly Profit & Loss
All figures in USD
Enanta Pharmaceuticals, Inc. Annual Profit & Loss
All figures in USD
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Enanta Pharmaceuticals, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $12.47 | $13.78 | +9.45% |
Jul 2026 | $14.83 | $12.59 | -13.50% |
Jun 2026 | $13.09 | $14.55 | +10.77% |
May 2026 | $13.92 | $13.14 | -5.26% |
Apr 2026 | $12.96 | $13.87 | +10.04% |
Mar 2026 | $14.14 | $12.61 | -11.17% |
Feb 2026 | $13.11 | $14.19 | +9.91% |
Jan 2026 | $15.35 | $12.91 | -18.63% |
Dec 2025 | $14.23 | $15.87 | +12.36% |
Nov 2025 | $11.03 | $14.12 | +29.30% |
Oct 2025 | $10.22 | $10.92 | -8.85% |
Sep 2025 | $8.59 | $11.98 | +42.79% |
ENTA Share Price FAQs
What is Enanta Pharmaceuticals, Inc. share price today?
What is the 52 week high and 52 week low of Enanta Pharmaceuticals, Inc. stock?
What is ENTA's market capitalisation today?
What is ENTA's net income for the last quarter?
What is the 5 year returns of ENTA?
What is the high & low stock price of ENTA today?
Can I buy ENTA shares in India?